Elizabeth Cespedes, ScD, of Kaiser Permanente Northern California in Oakland, and colleagues examined 2,470 Kaiser Permanente patients with CRC between stage I and stage III from 2006 through 2011. Approximately 1,219 patients were female with a mean age of 63 years.
Researchers measured for neutrophil-to-lymphocyte ratio. The control group had a ratio under three, which indicated low or no inflammation.
Here’s what they found:
1. A NLR ratio of 3 or greater and sarcopenia was common.
2. Over six years, 656 patients died with 357 deaths from CRC.
3. Researchers found NLR was associated with sarcopenia in a dose-response manner.
4. When a patient had a NLR of three or greater and exhibited sarcopenia independently, patients were two times more likely to die.
Researchers concluded, “Prediagnosis inflammation was associated with at-diagnosis sarcopenia. Sarcopenia combined with inflammation nearly doubled risk of death, suggesting that these commonly collected biomarkers could enhance prognostication. A better understanding of how the host inflammatory/immune response influences changes in skeletal muscle may open new therapeutic avenues to improve cancer outcomes.”
More articles on gastroenterology:
GI leader to know: Dr. Anil Sharma of Gastroenterology Group of Rochester
82% of early-onset CRC cases misdiagnosed — 10 study insights
Takeda, TiGenix’s complex perianal fistulas treatment receives 1st ever positive EMA opinion — 3 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.